Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The SOLD Randomized Clinical Trial

IMPORTANCE: Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. While the standard duration of trastuzumab treatment is 12 months, the benefits and harms of trastuzumab continued beyond the c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Joensuu, Heikki, Fraser, Judith, Wildiers, Hans, Huovinen, Riikka, Auvinen, Päivi, Utriainen, Meri, Nyandoto, Paul, Villman, Kenneth K., Halonen, Päivi, Granstam-Björneklett, Helena, Lundgren, Lotta, Sailas, Liisa, Turpeenniemi-Hujanen, Taina, Tanner, Minna, Yachnin, Jeffrey, Ritchie, Diana, Johansson, Oskar, Huttunen, Teppo, Neven, Patrick, Canney, Peter, Harvey, Vernon J., Kellokumpu-Lehtinen, Pirkko–Liisa, Lindman, Henrik
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143012/
https://ncbi.nlm.nih.gov/pubmed/29852043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados